Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.57 AUD | -2.80% | +1.32% | -8.94% |
Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 66 | 100.0 % | 78 | 100.0 % | +19.17% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe & United States
92.3
%
| 60 | 91.5 % | 72 | 92.3 % | +20.19% |
Switzerland, Others
7.7
%
| 6 | 8.5 % | 6 | 7.7 % | +8.19% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 05-10-31 |
Lachlan Hay
COO | Chief Operating Officer | - | 06-12-31 |
Dennis J. Wright
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Director/Board Member | - | 07-02-05 | |
Karen Agersborg
BRD | Director/Board Member | - | 18-01-28 |
Susan Smith
BRD | Director/Board Member | - | 19-09-22 |
Chairman | - | 19-11-25 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 50,127,270 | 39,883,495 ( 79.56 %) | 0 | 79.56 % |
Company contact information
Clinuvel Pharmaceuticals Ltd.
535 Bourke Street Level 11
3000, Melbourne
+61 3 9660 4900
http://www.clinuvel.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.94% | 489M | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
-21.76% | 29.48B | |
+55.64% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+4.42% | 8.75B |
- Stock Market
- Equities
- CUV Stock
- Company Clinuvel Pharmaceuticals Limited